Solid Neoplasm Clinical Trial
Official title:
ABT-888 as Monotherapy and in Combination With Mitomycin C in Patients With Solid Tumors With Deficiency in Homologous Recombination Repair
This phase I trial studies the side effects and best dose of veliparib when given with or without mitomycin C in treating patients with solid tumors that have spread to other places in the body, cannot be removed by surgery or have come back. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as mitomycin C, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib together with mitomycin C may kill more tumor cells.
PRIMARY OBJECTIVES:
I. To screen cancer patients across different histological sites to identify those with
functional defects in the Fanconi anemia (FA) pathway in their tumors.
II. To establish the safety and practicality of treating patients with FA deficient tumors
with the poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor ABT-888
(veliparib) as protracted monotherapy.
III. To establish the safety and practicality of treating patients with FA deficient tumors
with the combination of mitomycin C (MMC) and ABT-888.
IV. To select a dose of ABT-888 protracted monotherapy and a dose-schedule of the
combination of mitomycin C and ABT-888 in patients with FA deficient tumors for phase 2
trials.
SECONDARY OBJECTIVES:
I. To evaluate for germ-line FA repair deficiency and BRCA mutations in peripheral blood
mononuclear (PBMC) in patients receiving ABT-888 treatment.
II. To evaluate in PBMC samples for foci produced by the histone variant gamma-H2A histone
family, member X (H2AX) in patients receiving mitomycin C with or without ABT-888 in order
to assess any possible effect of ABT-888 in the cellular sensing and processing of mitomycin
C-induced deoxyribonucleic acid (DNA) double strand breaks.
III. Quantify the number of patients with antitumor responses.
OUTLINE: This is a dose-escalation study of veliparib. Patients are assigned to 1 of 2
treatment arms.
ARM I: Patients receive veliparib orally (PO) twice daily (BID) in the absence of disease
progression or unacceptable toxicity.
ARM II: Patients receive veliparib PO BID on days 1-7, 1-14, or 1-21. Patients also receive
mitomycin C intravenously (IV) over 10-20 minutes on day 1. Courses repeat every 28 days in
the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 12 weeks.
;
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02540876 -
Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery
|
Phase 1 | |
Suspended |
NCT04060849 -
Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY
|
Phase 1 | |
Active, not recruiting |
NCT03834961 -
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
|
Phase 2 | |
Completed |
NCT02897375 -
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04147494 -
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
|
Early Phase 1 | |
Completed |
NCT03775616 -
Financial Navigation Program Intervention in Supporting Patients With Solid Tumors and Their Caregivers
|
N/A | |
Active, not recruiting |
NCT03098277 -
Movement Tracking Devices to Monitor Physical Activity in Patients Undergoing Chemotherapy
|
N/A | |
Completed |
NCT00503854 -
Fatigue and Symptom Burden in Low-Risk Cancer Patients Undergoing Treatment for Febrile Neutropenia
|
||
Terminated |
NCT02414724 -
Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma
|
Phase 1 | |
Active, not recruiting |
NCT02876068 -
Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT02142803 -
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00085553 -
Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02867592 -
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
|
Phase 2 | |
Recruiting |
NCT03023202 -
UWCCC Molecular Tumor Board Registry
|
||
Active, not recruiting |
NCT02706366 -
Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT01552356 -
Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT02567396 -
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
|
Phase 1 | |
Completed |
NCT02360215 -
Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases
|
Phase 3 | |
Withdrawn |
NCT03804255 -
Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting
|
||
Completed |
NCT02646319 -
Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations
|
Early Phase 1 |